Lynn G Feun1, Macus Tien Kuo, Niramol Savaraj. 1. aSylvester Comprehensive Cancer Center, University of Miami, Miami, Florida bDepartment of Translational Molecular Pathology, The University of Texas MD, Anderson Cancer Center, Houston, Texas cSylvester Comprehensive Cancer Center, University of Miami, VA Medical Center, Miami, Florida, USA.
Abstract
PURPOSE OF REVIEW: There has been an increased and renewed interest in metabolic therapy for cancer, particularly Arg deprivation. The purpose of this review is to highlight recent studies that focus on Arg-dependent malignancies with Arginine (Arg)-degrading enzymes, including arginase and Arg deiminase. RECENT FINDINGS: New developments in this area include understanding of the role of most significantly downregulated gene regulating amino acid metabolism, argininosuccinate synthetase and its expression and therapeutic relevance in different tumors. Recent studies have also shed light on the mechanism of tumor cell death with Arg deprivation, with arginase and pegylated Arg deiminase. Particularly important is understanding the mechanism of resistance that cancers develop after such drug exposure. Finally, recent clinical trials have been performed or are ongoing to use Arg deprivation as treatment for advanced malignancies. SUMMARY: Arg deprivation is a promising approach for the treatment of various malignancies.
PURPOSE OF REVIEW: There has been an increased and renewed interest in metabolic therapy for cancer, particularly Arg deprivation. The purpose of this review is to highlight recent studies that focus on Arg-dependent malignancies with Arginine (Arg)-degrading enzymes, including arginase and Arg deiminase. RECENT FINDINGS: New developments in this area include understanding of the role of most significantly downregulated gene regulating amino acid metabolism, argininosuccinate synthetase and its expression and therapeutic relevance in different tumors. Recent studies have also shed light on the mechanism of tumor cell death with Arg deprivation, with arginase and pegylated Arg deiminase. Particularly important is understanding the mechanism of resistance that cancers develop after such drug exposure. Finally, recent clinical trials have been performed or are ongoing to use Arg deprivation as treatment for advanced malignancies. SUMMARY:Arg deprivation is a promising approach for the treatment of various malignancies.
Authors: Seong M Kim; Saurabh G Roy; Bin Chen; Tiffany M Nguyen; Ryan J McMonigle; Alison N McCracken; Yanling Zhang; Satoshi Kofuji; Jue Hou; Elizabeth Selwan; Brendan T Finicle; Tricia T Nguyen; Archna Ravi; Manuel U Ramirez; Tim Wiher; Garret G Guenther; Mari Kono; Atsuo T Sasaki; Lois S Weisman; Eric O Potma; Bruce J Tromberg; Robert A Edwards; Stephen Hanessian; Aimee L Edinger Journal: J Clin Invest Date: 2016-09-26 Impact factor: 14.808
Authors: Ubaldo E Martinez-Outschoorn; Maria Peiris-Pagés; Richard G Pestell; Federica Sotgia; Michael P Lisanti Journal: Nat Rev Clin Oncol Date: 2016-05-04 Impact factor: 66.675
Authors: Lindsay C Burrage; Qin Sun; Sarah H Elsea; Ming-Ming Jiang; Sandesh C S Nagamani; Arthur E Frankel; Everett Stone; Susan E Alters; Dale E Johnson; Scott W Rowlinson; George Georgiou; Brendan H Lee Journal: Hum Mol Genet Date: 2015-09-10 Impact factor: 6.150